Shares of Biodel Inc. shot up 19 percent on the first day of trading, as the company priced its initial public offering of 5 million shares at $15 apiece for gross proceeds of $75 million. (BioWorld Today)
The Human Genome Project had yet to be completed and only one targeted cancer therapy was on the market when attendees of the annual BIO International Convention descended on Boston in March 2000. (BioWorld Today)
The Human Genome Project had yet to be completed and only one targeted cancer therapy was on the market when attendees of the annual BIO International Convention descended on Boston in March 2000. (BioWorld Today)
